سعر انجيوبلوك 300/25 مجم 30 قرص 2025

Fixed-dose oral film-coated tablets of irbesartan 300 mg and hydrochlorothiazide 25 mg (Angioblock, Global Napi Pharmaceuticals/GAP, Egypt); 30 tablets per pack.

• Treatment of essential hypertension in adults whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (fixed-dose combination)Population: AdultsEuropean Medicines Agency (EMA)

• Most common in placebo-controlled trials: dizziness (5.6%), fatigue (4.9%), nausea/vomiting (1.8%), abnormal urination (1.4%); increases in BUN (2.3%), creatine kinase (1.7%) and creatinine (1.1%).International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to the active substances, any excipient or other sulfonamide-derived substances.International label, same formulation · European Medicines Agency (EMA)
• Second and third trimesters of pregnancy.International label, same formulation · European Medicines Agency (EMA)
• Severe renal impairment (creatinine clearance <30 mL/min); refractory hypokalaemia; hypercalcaemia; severe hepatic impairment, biliary cirrhosis and cholestasis.International label, same formulation · European Medicines Agency (EMA)

• Symptomatic hypotension in volume/sodium-depleted patients; increased risk of severe hypotension and renal insufficiency in renal artery stenosis.International label, same formulation · European Medicines Agency (EMA)
• Dual RAAS blockade (ACE inhibitors, ARBs or aliskiren) not recommended.International label, same formulation · European Medicines Agency (EMA)
• Electrolyte imbalance (hypo/hyperkalaemia, hyponatraemia), hyperuricaemia, impaired glucose tolerance; lithium combination not recommended.International label, same formulation · European Medicines Agency (EMA)

• LithiumIncreased lithium levels and toxicity; combination not recommended - monitor levels if necessary.European Medicines Agency (EMA)
• Potassium-sparing diuretics, potassium supplements, salt substitutes, heparinIncrease in serum potassium; monitor.European Medicines Agency (EMA)
• NSAIDs (including COX-2 inhibitors and aspirin >3 g/day)Attenuated antihypertensive effect and risk of worsening renal function; hydrate and monitor renal function.European Medicines Agency (EMA)

• AIIRAs are not recommended in the first trimester and are contraindicated in the second and third trimesters; hydrochlorothiazide is not recommended in the first trimester. Switch to an alternative before a planned pregnancy.International label, same formulation · European Medicines Agency (EMA)
• Not recommended during breastfeeding (no data for irbesartan; hydrochlorothiazide is excreted in small amounts and high doses may inhibit milk production).International label, same formulation · European Medicines Agency (EMA)

English text not available for this section.